Video

Dr. Stratigos on the Prevention of Melanoma

Author(s):

Alexander J. Stratigos, MD

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

Primary prevention is an approach that aims to reduce the exposure of UV radiation on human skin. The primary goals are to reduce the exposure through the use of sunscreen and protective clothing, explains Stratigos.

There is also prevention that aims to protect vulnerable populations such as children or outdoor workers. According to Stratigos, it is important for physicians to understand the early clues of skin cancer to better educate their patients on the importance of prevention.

<<<

View more from the European Post-Chicago Meeting

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.
Related Content
Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Hope S. Rugo, MD, of University of California, San Francisco
July 19th 2024

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer

Lynn M. Schuchter, MD, of Penn Medicine
July 16th 2024

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers